Last edition
News about "TREMFYA "
Johnson & Johnson Submits FDA Approval for SC Induction Regimen of TREMFYA in Ulcerative Colitis
TREMFYA® is the first and only approved, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.
TREMFYA | 25/11/2024 | By Aishwarya
Johnson & Johnson Gets US FDA Approval for TREMFYA
TREMFYA is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.
TREMFYA | 12/09/2024 | By Aishwarya
Johnson & Johnson Submits Application to US FDA Seeking Approval of TREMFYA
Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of TREMFYA (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease.
TREMFYA | 21/06/2024 | By Aishwarya | 262
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy